Form 4: Cadrenal Therapeutics Director Acquires 20,000 Stock Options

Robert Lisicki, a director at Cadrenal Therapeutics, acquired 20,000 stock options on January 23, 2025.

Summary

• Robert Lisicki, a director of Cadrenal Therapeutics, acquired 20,000 stock options on January 23, 2025.
• The options have an exercise price of $19.79.
• The options vest monthly over 12 months, starting February 1, 2025.
• The options expire on January 22, 2035.

Sentiment

Score: 6

Explanation: The document is a routine filing and does not contain any information that would significantly impact sentiment. It is a neutral event.

Positives

• The acquisition of stock options by a director could indicate confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who acquire or dispose of company securities. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as a form of compensation and incentive.
• The vesting schedule of 12 months is also a typical arrangement to align the director's interests with the company's long-term performance.
• The exercise price of $19.79 is a specific value for this grant and would need to be compared to other grants to determine if it is in line with industry standards.

Stakeholder Impact

• The acquisition of stock options by a director may be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, Cadrenal Therapeutics, director, insider trading, equity, CVKD